Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothal
Go back to Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothal| (NASDAQ: RYTM) | Delayed: 106.19 +4.80 (4.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $101.39 | 52 Week High | $ | |||
| Open | $101.00 | 52 Week Low | $ | |||
| Day High | $107.00 | P/E | N/A | |||
| Day Low | $99.49 | EPS | $ | |||
| Volume | 1,289,030 | |||||
